Research Papers:
MicroRNA-218 inhibits proliferation and invasion in ovarian cancer by targeting Runx2
Metrics: PDF 1918 views | HTML 3069 views | ?
Abstract
Na Li1, Lufei Wang2, Guangyun Tan3, Zhiheng Guo1, Lei Liu1, Ming Yang4,* and Jin He1,*
1Department of Gynecology and Obstetrics, The First Hospital of Jilin University, Changchun, Jilin 130021, PR China
2Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin 130022, PR China
3Department of Immunology, Institute of Translational Medicine of The First Hospital of Jilin University, Changchun, Jilin 130021, PR China
4Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, PR China
*These authors have contributed equally to this work
Correspondence to:
Ming Yang, email: [email protected]
Jin He, email: [email protected]
Keywords: MiR-218, ovarian cancer, RUNX2, proliferation, invasion
Received: April 07, 2017 Accepted: July 19, 2017 Published: September 16, 2017
ABSTRACT
MicroRNA-218 (miR-218) has been implicated in the development and progression of multiple cancers. We investigated the role of miR-218 in ovarian cancer progression. We found that miR-218 expression levels were lower in ovarian cancer tissues and cell lines than in adjacent normal tissues or a normal ovarian cell line.miR-218 levels associated with International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastasis. Exogenous expression of miR-218 inhibited cell proliferation, colony formation, migration, and invasion in vitro and suppressed tumor growth in a tumor-bearing nude mouse model. Runt-related transcription factor 2 (RUNX2) was identified as a direct functional target of miR-218, and its expression was inversely correlated with miR-218 expression in ovarian cancer tissues. RUNX2 overexpression rescued the suppressive effect of miR-218 on ovarian cancer cell proliferation, colony formation, migration, and invasion. These findings highlight an important role played bymiR-218 in the regulation of cancer growth and metastasis, in part by repressing RUNX2, and revealed the potential of miR-218 as a new therapeutic target inovarian cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21069